Compare Figma Inc. Class A Common Stock (FIG) vs ImmunityBio Inc. Common Stock (IBRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Figma Inc. Class A Common Stock vs ImmunityBio Inc. Common Stock — how do they compare? Figma Inc. Class A Common Stock trades at $21.24 (market cap $11.60B), while ImmunityBio Inc. Common Stock trades at $9.99 (market cap $10.39B). The key difference: Figma Inc. Class A Common Stock and ImmunityBio Inc. Common Stock are close in size by market cap, and ImmunityBio Inc. Common Stock is trading nearer its 52-week high, Figma Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Figma Inc. Class A Common Stock for 0 Days and ImmunityBio Inc. Common Stock for 6 Days on average.
| FIG | IBRX | |
|---|---|---|
Market Cap | $11.60B | $10.39B |
Volume | 12,281,013 | 11,509,049 |
Sector | Technology | Health |
52-Week High | $63.82 | $11.55 |
52-Week Low | $16.84 | $1.98 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $10.00B | $10.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
ImmunityBio (IBRX) trades at $9.80, down 3.16% on the day, amid a bullish technical setup and strong analyst support. The company reported revenue growth to $166 million in 2026 but remains deeply unprofitable with a net loss of $992 million. Recent FDA approval expansion for ANKTIVA in bladder cancer and high-profile executive appointments signal operational momentum, though cash burn remains a concern with negative operating cash flow.
Outlook is cautiously optimistic given the unanimous buy ratings and regulatory milestones, but investment carries high risk due to persistent losses, heavy reliance on financing, and competitive pressures. The stock's trajectory hinges on successful commercialization and pipeline execution to achieve profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Figma Inc. Class A Common Stock
Figma, Inc. is a US software company that operates a collaborative interface design and product development platform used by design and engineering teams to create, prototype, and build digital products.
Read more on FIG →About ImmunityBio Inc. Common Stock
ImmunityBio develops immune-based therapies for cancer and infectious diseases. Its programs are designed to activate and strengthen the body’s immune response.
Read more on IBRX →
